Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Cash & Equivalents: 2013-2025

Historic Cash & Equivalents for Fortress Biotech (FBIO) over the last 13 years, with Sep 2025 value amounting to $86.2 million.

  • Fortress Biotech's Cash & Equivalents rose 46.50% to $86.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $86.2 million, marking a year-over-year increase of 46.50%. This contributed to the annual value of $57.3 million for FY2024, which is 29.24% down from last year.
  • According to the latest figures from Q3 2025, Fortress Biotech's Cash & Equivalents is $86.2 million, which was up 15.91% from $74.4 million recorded in Q2 2025.
  • Over the past 5 years, Fortress Biotech's Cash & Equivalents peaked at $305.7 million during Q4 2021, and registered a low of $57.3 million during Q4 2024.
  • Moreover, its 3-year median value for Cash & Equivalents was $78.0 million (2023), whereas its average is $82.9 million.
  • As far as peak fluctuations go, Fortress Biotech's Cash & Equivalents soared by 113.25% in 2021, and later tumbled by 68.64% in 2023.
  • Over the past 5 years, Fortress Biotech's Cash & Equivalents (Quarterly) stood at $305.7 million in 2021, then tumbled by 41.69% to $178.3 million in 2022, then crashed by 54.60% to $80.9 million in 2023, then declined by 29.24% to $57.3 million in 2024, then skyrocketed by 46.50% to $86.2 million in 2025.
  • Its last three reported values are $86.2 million in Q3 2025, $74.4 million for Q2 2025, and $91.3 million during Q1 2025.